From White House trade actions to critical RFIs, this week’s update keeps MedTech leaders aligned on emerging priorities.
In Week 5, the spotlight is on international trade and regulatory engagement. The White House announced new tariff actions on Chinese imports, including select medical technologies. AdvaMed is reviewing the implications and preparing formal comments, requesting member input to shape the response. The update also highlights several open RFIs—DOJ’s Anticompetitive Regulations Task Force, CMS’s Medicare Regulatory Relief RFI, and HHS’s request to identify burdensome healthcare regulations. Members are encouraged to submit comments before deadlines in May and June. Additionally, AdvaMed is finalizing comments on the USTR Section 301 investigation into China’s shipbuilding practices. As Washington ramps up regulatory activity, AdvaMed remains active in coordinating with members, gathering data, and representing the MedTech industry’s interests.